DuPont Merck Pharmaceuticals
Drops interleukin-1 therapeutic research under a renegotiated agreement with Cistron, the company announced Aug. 7. DuPont had licensed IL-1 from Cistron in 1985, and the license was assigned to DuPont Merck when that company was formed last year. Under the new agreement, DuPont will have rights to IL-1 for the research market, and Cistron will be free to seek new partners for IL-1 therapeutics.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth